## EG: Everest Group, Ltd. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 3.4% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($323.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Trueman and Shaw take senior roles at Everest wholesale and specialty**
- Source: Global Reinsurance | 20251222T140828 | Bullish | Relevance: 100%
- Everest Group has appointed Paul Trueman as head of international and Mark Shaw as global head of commercial within its global wholesale and specialty insurance division. These appointments are effective immediately and are part of Everest's strategy to strengthen its wholesale and specialty platform, focusing on disciplined underwriting and closer broker alignment. Both Trueman and Shaw joined Everest in 2022 and have significant experience in the specialty insurance market.

**2. Global: Everest announces leadership appointments**
- Source: Asia Insurance Review | 20251222T000358 | Bullish | Relevance: 100%
- Everest Group has appointed Mr. Mark Shaw as Global Head of Commercial, Global Wholesale and Specialty and Mr. Paul Trueman as Head of International, Global Wholesale and Specialty. Mr. Shaw will lead the firm’s global commercial insurance strategy, while Mr. Trueman will oversee underwriting, distribution, and portfolio strategy across international markets. Both joined Everest in 2022 and have been instrumental in enhancing the company's market reach and specialty capabilities.

**3. Brighton Jones LLC Purchases 4,062 Shares of Everest Group, Ltd. $EG**
- Source: MarketBeat | 20251223T084801 | Neutral | Relevance: 100%
- Brighton Jones LLC increased its stake in Everest Group, Ltd. (NYSE:EG) by 157.9% in the third quarter, acquiring an additional 4,062 shares to bring its total holdings to 6,635 shares valued at $2.324 million. Despite missing EPS expectations, Everest Group reported strong revenue and institutional investors own a significant portion of its stock. The company also declared a quarterly dividend of $2.00, and insider buying has been noted.

**4. SLK, an Altimetrik Company named Major Contender in Everest Group's Application Transformation Services for AI-enablement PEAK Matrix® Assessment 2025**
- Source: PR Newswire | 20251224T070040 | Somewhat-Bullish | Relevance: 91%
- SLK, an Altimetrik Company, has been recognized as a Major Contender in Everest Group's Application Transformation Services for AI-enablement PEAK Matrix® Assessment 2025, highlighting its AI-first vision. This recognition underscores their ability to help enterprises build intelligent, adaptive, and data-driven ecosystems ready for the AI era by modernizing legacy systems into cloud-native, data-rich, API-first architectures. SLK's approach combines AI-infused and AI-native transformation, leveraging proprietary tools and domain expertise to drive AI adoption at scale across various industries.

**5. SiriusPoint’s IMG to acquire travel assistance provider Assist America**
- Source: Investing.com | 20251223T130929 | Somewhat-Bullish | Relevance: 62%
- SiriusPoint Ltd.'s wholly owned subsidiary, International Medical Group (IMG), is set to acquire Assist America, a global emergency travel assistance provider. This acquisition aims to strengthen IMG’s medical and travel assistance revenue, expand its U.S. market presence, and extend its coverage into Asia and the Middle East. The transaction is expected to be accretive to SiriusPoint's return on equity and earnings per share, adding capital-light fee income.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Mizuho | $359 | $0 | 0% |
| 2025-12-15 | TD Cowen | $365 | $400 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Mizuho | init | Neutral |
| 2025-12-15 | TD Cowen | main | Hold |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (-1.0%)
- Blackrock Inc.: 8.1% (-2.9%)
- AQR Capital Manageme: 4.8% (+70.3%)
- State Street Corpora: 4.5% (-0.7%)
- Vulcan Value Partner: 3.4% (+13.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 6.1x attractive for 24% earnings growth. Balance sheet: strong liquidity (11.3x). Revenue declining -7% YoY, concerning. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.1B |
| Beta | 0.38 |
| 52W Range | $302.44 - $373.23 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -50.00 |
| Forward P/E | 6.1 |
| Current P/E | 7.5 |
| YoY Growth | 24.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.9% to 3.4% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.6pp (needs >4.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.6% shows strong absolute momentum above own 20MA. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (2.57), confirming momentum. OFD pattern: -STL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.42% (CS: 85) | Neutral |
| RSI_14 | 65.1 | Neutral |
| MACD Histogram | 2.57 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 0.992x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $336.29
- **Stop Loss:** $323.89 (3.7% risk)
- **Target:** $348.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 116
- **Position Value:** $39,009.64
- **Portfolio %:** 39.01%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-02 (Est: $13.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $14.52 | $7.54 | -48.1% |
| 2025Q2 | $14.82 | $17.36 | +17.1% |
| 2025Q1 | $7.74 | $6.45 | -16.7% |
| 2024Q4 | $-17.42 | $-18.39 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*